Complement Is Key: Exploring the Role of C5-Targeted Therapies in Generalized Myasthenia Gravis

Please visit answersincme.com/860/MED-HEM-04146-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tuan H. Vu, MD. In this activity, experts in generalized myasthenia gravis discuss evidence-based strategies for optimal use of C5-targeted therapies. Upon completion of this activity, participants should be better able to: Assess the rationale for C5-targeted therapies in patients with generalized myasthenia gravis (gMG). Individualize C5-targeted therapy for appropriate patients with gMG based on available evidence. Formulate patient-centered, evidence-based strategies for optimizing integration of C5-targeted therapies for gMG as they become available. This activity will be held during the AANEM Annual Meeting. It is not part of the official scientific program of the AANEM.